MediWound Analyst Ratings
MediWound Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/17/2023 | 157.85% | HC Wainwright & Co. | → $23 | Reiterates | Buy → Buy |
| 05/31/2023 | 606.28% | Oppenheimer | → $63 | Reiterates | Outperform → Outperform |
| 05/31/2023 | 157.85% | HC Wainwright & Co. | → $23 | Reiterates | Buy → Buy |
| 03/17/2023 | 157.85% | HC Wainwright & Co. | → $23 | Reiterates | → Buy |
| 01/04/2023 | 157.85% | HC Wainwright & Co. | $5.5 → $23 | Maintains | Buy |
| 12/30/2022 | 180.27% | Cowen & Co. | $6 → $25 | Maintains | Outperform |
| 12/22/2022 | 180.27% | Maxim Group | → $25 | Initiates Coverage On | → Buy |
| 12/21/2022 | 606.28% | Oppenheimer | $9 → $63 | Maintains | Outperform |
| 11/16/2022 | -38.34% | HC Wainwright & Co. | $6 → $5.5 | Maintains | Buy |
| 07/18/2022 | -21.52% | Oppenheimer | → $7 | Assumes | → Outperform |
| 05/18/2022 | -10.31% | Wells Fargo | $7 → $8 | Maintains | Overweight |
| 03/21/2022 | -21.52% | Aegis Capital | $9 → $7 | Maintains | Buy |
| 08/17/2021 | 0.9% | Aegis Capital | $10 → $9 | Maintains | Buy |
| 08/11/2021 | -27.13% | HC Wainwright & Co. | $7 → $6.5 | Maintains | Buy |
| 03/02/2021 | 12.11% | Aegis Capital | → $10 | Initiates Coverage On | → Buy |
| 09/23/2020 | -32.74% | BTIG | → $6 | Initiates Coverage On | → Buy |
| 08/05/2019 | -38.34% | HC Wainwright & Co. | → $5.5 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/17/2023 | 157.85% | HC Wainwright & Co. | → 23 美元 | 重申 | 購買 → 購買 |
| 05/31/2023 | 606.28% | 奧本海默 | → 63 美元 | 重申 | 跑贏大盤 → 跑贏大盤 |
| 05/31/2023 | 157.85% | HC Wainwright & Co. | → 23 美元 | 重申 | 購買 → 購買 |
| 03/17/2023 | 157.85% | HC Wainwright & Co. | → 23 美元 | 重申 | → 購買 |
| 2023 年 4 月 1 日 | 157.85% | HC Wainwright & Co. | 5.5 美元 → 23 美元 | 維護 | 購買 |
| 12/30/2022 | 180.27% | Cowen & Co. | 6 美元 → 25 美元 | 維護 | 跑贏大盤 |
| 2022 年 12 月 22 日 | 180.27% | Maxim 集團 | → 25 美元 | 啓動覆蓋開啓 | → 購買 |
| 2022 年 12 月 21 日 | 606.28% | 奧本海默 | 9 美元 → 63 美元 | 維護 | 跑贏大盤 |
| 11/16/2022 | -38.34% | HC Wainwright & Co. | 6 美元 → 5.5 美元 | 維護 | 購買 |
| 07/18/2022 | -21.52% | 奧本海默 | → 7 美元 | 假設 | → 跑贏大盤 |
| 05/18/2022 | -10.31% | 富國銀行 | 7 美元 → 8 美元 | 維護 | 超重 |
| 03/21/2022 | -21.52% | 宙斯盾資本 | 9 美元 → 7 美元 | 維護 | 購買 |
| 2021 年 8 月 17 日 | 0.9% | 宙斯盾資本 | 10 美元 → 9 美元 | 維護 | 購買 |
| 08/11/2021 | -27.13% | HC Wainwright & Co. | 7 美元 → 6.5 美元 | 維護 | 購買 |
| 2021 年 2 月 3 日 | 12.11% | 宙斯盾資本 | → 10 美元 | 啓動覆蓋開啓 | → 購買 |
| 2020 年 9 月 23 日 | -32.74% | BTIG | → 6 美元 | 啓動覆蓋開啓 | → 購買 |
| 2019 年 5 月 8 日 | -38.34% | HC Wainwright & Co. | → 5.5 美元 | 啓動覆蓋開啓 | → 購買 |
What is the target price for MediWound (MDWD)?
MediWound (MDWD) 的目標價格是多少？
The latest price target for MediWound (NASDAQ: MDWD) was reported by HC Wainwright & Co. on August 17, 2023. The analyst firm set a price target for $23.00 expecting MDWD to rise to within 12 months (a possible 157.85% upside). 9 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年8月17日公佈了MediWound（納斯達克股票代碼：MDWD）的最新目標股價。該分析公司將目標股價定爲23.00美元，預計MDWD將在12個月內上漲至157.85％（可能上漲157.85％）。去年有9家分析公司公佈了評級。
What is the most recent analyst rating for MediWound (MDWD)?
MediWound (MDWD) 的最新分析師評級是多少？
The latest analyst rating for MediWound (NASDAQ: MDWD) was provided by HC Wainwright & Co., and MediWound reiterated their buy rating.
HC Wainwright & Co. 提供了MediWound（納斯達克股票代碼：MDWD）的最新分析師評級，MediWound重申了買入評級。
When is the next analyst rating going to be posted or updated for MediWound (MDWD)?
MediWound（MDWD）的下一份分析師評級何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of MediWound, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for MediWound was filed on August 17, 2023 so you should expect the next rating to be made available sometime around August 17, 2024.
分析師在進行了廣泛的研究後得出了股票評級，包括閱讀公開財務報表、與MediWound的高管和客戶交談以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。MediWound的最後一次評級是在2023年8月17日提交的，因此你應該預計下一個評級將在2024年8月17日左右公佈。
Is the Analyst Rating MediWound (MDWD) correct?
分析師對MediWound (MDWD) 的評級是否正確？
While ratings are subjective and will change, the latest MediWound (MDWD) rating was a reiterated with a price target of $0.00 to $23.00. The current price MediWound (MDWD) is trading at is $8.92, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但重申了最新的MediWound（MDWD）評級，目標股價爲0.00美元至23.00美元。MediWound（MDWD）目前的交易價格爲8.92美元，在分析師的預測區間內。